| |
Ineligible group |
Borderline group |
Eligible group* |
| Strategy |
Total cost per patient ($) |
Total QALYs per patient |
ICER* |
Total cost per patient ($) |
Total QALYs per patient |
ICER* |
Total cost per patient ($) |
Total QALYs per patient |
ICER* |
| Natural history |
21,229 |
16.06 |
- |
33,280 |
12.38 |
- |
32,430 |
12.24 |
|
| Monitor & Treat |
21,550 |
19.36 |
97 |
37,043 |
19.92 |
500 |
42,711 |
21.33 |
1,131 |
| Reduction in ETV price by 5% |
20,752 |
19.36 |
cost saving |
35,196 |
19.92 |
254 |
40,243 |
21.33 |
860 |
| Reduction in ETV price by 50% |
14,794 |
19.36 |
cost saving |
21,622 |
19.92 |
cost saving |
22,164 |
21.33 |
cost saving |
US$ per QALY gained
*Patients eligible under the APASL treatment guideline |
